The news story you are looking for has expired. A more recent related article is displayed below.

Sponsored Links

Repros Therapeutics Secures Financing

Sep 12, 2009 (Close-Up Media via COMTEX) --

Company: Repros Therapeutics Inc (RPRX)

Repros Therapeutics announced that Repros has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.

In a release, the Company noted that this financing will allow Repros to continue its business activity for the near term and provide it with more flexibility to continue exploring various strategic alternatives. The offering is expected to close on or about September 11, subject to the satisfaction of customary closing conditions.

Repros Therapeutics focuses on the development of oral small molecule drugs for unmet medical needs that treat male and female reproductive disorders.

((Comments on this story may be sent to health@closeupmedia.com))

Copyright (C) 2009 Close-Up Media. All rights reserved

News Provided by COMTEX

Company: Repros Therapeutics Inc (RPRX)


Related terms: business, drugs, health, medical

Related Articles

Repros Therapeutics to raise $4.4 million in financing - Zibb.com
Oct 12, 2009
Repros Therapeutics to raise $4.4 million in financing Repros Therapeutics has entered into a...million shares of its common stock at $1.27 per share...4.4 million. Repros Therapeutics focuses on the development...

CF sweetens bid for US rival Terra with $3.2bn cash
Nov 2, 2009
...of $32.00 in cash and 0.1034 of a share of CF common stock for each Terra share. The offer is worth $40...share, based on the 30 October closing price for CF common stock, CF said. CF calculated the offer to be a premium...

A Three-Way Strategy on Repros Therapeutics
Oct 26, 2009
...Cap A Three-Way Strategy on Repros Therapeutics 1 comment by: optionMONSTER...Russell Options activity surged in Repros Therapeutics (RPRX) on Friday, less than...Articles A Three-Way Strategy on Repros Therapeutics Oct 26, 2009 Spectrum Pharma...

Journal Communications Reports Third Quarter 2009 Results
Oct 21, 2009
...earnings per share of class A and B common stock were $0.02 for both. Excluding...earnings per share of class A and B common stock were $0.08 for both. This compared...earnings per share of class A and B common stock were $0.16 for both. EBITDA...